Date: 2016-10-19
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Curis (USA - MA)
Product: small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4)
Action
mechanism: kinase inhibitor. IRAK4 is a serine/ threonine kinase involved in the regulation of innate immune responses and also plays an important role in certain hematologic cancers. IRAK4 is inappropriately activated, and drives pro-survival and cytokine mediated pathways in cancers such as activated B cell-diffuse large B cell lymphoma (ABC-DLBCL), an aggressive form of lymphoma with poor prognosis. Targeting IRAK4 has potential therapeutic implications in both cancer and cytokine-driven inflammatory and autoimmune diseases.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On October 19, 2015, Curis announced the expansion of its pipeline with the addition of a small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4). The additions to the pipeline come through the Company's exercise of its options under a collaboration agreement with Aurigene announced earlier this year. Curis also exercised its option to exclusively license a program of orally available small molecule inhibitors of IRAK4 kinase. IRAK4 is a serine/ threonine kinase involved in the regulation of innate immune responses and also plays an important role in certain hematologic cancers. IRAK4 is inappropriately activated, and drives pro-survival and cytokine mediated pathways in cancers such as activated B cell-diffuse large B cell lymphoma (ABC-DLBCL), an aggressive form of lymphoma with poor prognosis. Targeting IRAK4 has potential therapeutic implications in both cancer and cytokine-driven inflammatory and autoimmune diseases. The exercise of options for the PD-L1/VISTA and IRAK4 programs resulted in an aggregate one-time payment of $6 million by Curis to Aurigene in exchange for an exclusive, royalty-bearing license to develop, manufacture and commercialize compounds from the programs, including the development candidate, CA-170 and products containing such compounds, anywhere in the world with the exception of India and Russia, where Aurigene will hold an exclusive, royalty-free, fully paid license to commercialize such compounds.
